ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2020
Plasma Adipsin as a Biomarker and Its Implication in Type 2 Diabetes Mellitus.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Sex-specific efficacy of curcumin-loaded nanoparticles and insulin for ocular-cardiac complications in type 2 diabetes mice.iScience · 2026Article
- Type 2 and type 1 diabetes have opposing effects on the systemic murine complement alternative pathway.iScience · 2026Article
- Circulating Adipsin as a Biomarker of Liver Fat Content in Prepubertal Children Born Small-for-Gestational-Age.International journal of molecular sciences · 2026Article
- Identification of potential therapeutic targets for complement-associated glomerular diseases using Mendelian randomization.Medicine · 2025Article
- Unraveling the complexities of diet induced obesity and glucolipid dysfunction in metabolic syndrome.Diabetology & metabolic syndrome · 2025Review
- Increased Plasma Levels of ACE and Ang II in Prediabetes May Contribute to Adipose Tissue Dysfunction.International journal of molecular sciences · 2025Observational
- Integrating adipsin with novel cardiometabolic and inflammatory indices for enhanced early prediction of gestational diabetes mellitus: a prospective cohort study.Cardiovascular diabetology · 2025Article
- The value of growth differentiation factor 15 as a biomarker for peripheral artery disease in diabetes patients.Diabetology & metabolic syndrome · 2025Article
- Adipose tissue-derived adipsin marks human aging in non-type 2 diabetes population.BMJ open diabetes research & care · 2024Article
- Association of Serum Adipsin Level with Insulin Resistance and Inflammatory Markers in Newly Diagnosed Type two Diabetes Mellitus Patients.Indian journal of clinical biochemistry : IJCB · 2024Article
- Adipokines and their role in acute pancreatitis.Journal of medical biochemistry · 2024Article
- TM4SF19-mediated control of lysosomal activity in macrophages contributes to obesity-induced inflammation and metabolic dysfunction.Nature communications · 2024Article
- Adipsin in the pathogenesis of cardiovascular diseases.Vascular pharmacology · 2024Review
- Adipsin and Leptin Levels in Type 2 Diabetic Patients on Sitagliptin and Metformin Versus Metformin Therapy.Sisli Etfal Hastanesi tip bulteni · 2024Article
- Role of complement factor D in cardiovascular and metabolic diseases.Frontiers in immunology · 2024Review
- Review
- Increased Serum Adipsin Correlates with MAFLD and Metabolic Risk Abnormalities.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Article
- Adipose Tissue Secretion Pattern Influences β-Cell Wellness in the Transition from Obesity to Type 2 Diabetes.International journal of molecular sciences · 2022Review
- Contribution of proteases to the hallmarks of aging and to age-related neurodegeneration.Aging cell · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a worldwide health threat affecting millions of people, which is associated with different micro- and macro-vascular complications. Type 2 diabetes mellitus (T2DM) is one of the different types of DM caused by insulin resistance and/or reduced secretion of insulin from the pancreas. A validated novel biomarker is required to enhance the accuracy of disease prediction, provide novel insights into pathophysiology and contribute to future prevention of T2DM. Various newer diagnostic methods have been developed by targeting endogenous proteins among which Adipsin is one of the promising target. Therefore, this review discusses Adipsin as a potential biomarker and its implication in T2DM. Adipsin is one of the adipokines secreted by adipose tissues which is involved in maintaining adipose tissue homeostasis and increasing insulin secretion in response to glucose. According to different experimental and clinical studies, plasma Adipsin concentrations are low in animals and patients with DM which support its use as a biomarker in combination to the other diagnostic modalities for DM. Additionally, the existence of Adipsin could be important in improving hyperglycemia by preserving β-cell mass through improving β-cell survival and maintaining their transcriptional identity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.